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Abstract 
Heart failure with preserved ejection fraction (HFpEF) constitutes approximately 50% of heart failure patients. The prevalence of 
diabetes mellitus in HFpEF is high at 30-40%. The paper provides a systematic review of the pathophysiological features 
underlying HFpEF in diabetes mellitus. The importance of mechanisms other than left ventricular diastolic dysfunction underlying 
this important condition is emphasised. Thus, ventricular-arterial coupling & vascular dysfunction together with chronotropic 
incompetence & cardiovascular reserve dysfunction play an important role. The various morphologic and molecular features 
occurring in the myocardium and vasculature in diabetes secondary to hyperglycaemia and other metabolic disturbances are also 
discussed. These include microangiopathy, myocardial fibrosis, increased oxidative stress, impaired calcium homeostasis, 
activation of the cardiac renin-angiotensin system, autonomic neuropathy, endothelial dysfunction, re-expression of foetal gene 
response as well as stem cell involvement. Nonetheless, a lot is still unknown and further studies are needed to establish the 
underlying pathophysiological mechanisms with the hope that novel pharmacotherapies targeting this disease will be 
developed. In the meantime, cardiometabolic factors, including hyperglycaemia, hypertension and dyslipidaemia should be 
targeted and aggressively treated.
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Background
In the past decade, there has been increasing interest in patients 
with signs and symptoms of heart failure (HF) despite a normal 
or near-normal left ventricular (LV) systolic function, for which 
the term “heart failure with preserved ejection fraction” (HFpEF) 
has been introduced. HFpEF constitutes approximately 50% of HF 
patients [1]. The Cardiovascular Health Study [2] suggests that it 
may be even commoner amongst patients with heart failure in the 
community and in women.
In the past, HFpEF was referred to as “diastolic heart failure” as 
opposed to “systolic heart failure” which relates to HF with reduced 
ejection fraction (HFrEF). However, there is now increasing emphasis 
on abandoning the terms diastolic/systolic HF since mechanisms other 
than diastolic dysfunction may contribute to HFpEF and an element 
of diastolic dysfunction exists in most cases of HFrEF [3]. The term 
‘heart failure with preserved systolic function’ has also been used by 
some authors but the term HFpEF is preferable since parameters of 
systolic function other than EF may be abnormal. The problem with 
the present terminology and diagnostic criteria is that HFpEF cannot 
be diagnosed in subjects with low EF, even if diastolic dysfunction 
contributes significantly to their symptoms and prognosis. This 
problem can only be resolved if the diagnosis of HFpEF be based 
on only positive criteria or if the diagnosis is allowed in subjects in 
whom clinical or biochemical manifestations of heart failure are 
disproportionate to the degree of reduction in EF.
The differentiation between HFpEF from HFrEF is not only of academic 
interest but is also useful in clinical practice since medications used 
in the treatment of HFrEF have been disappointing in HFpEF. This 
observation also suggests that HFpEF is a separate pathophysiological 
entity [4]. Nonetheless, others argue that HFpEF and HFrEF are not 
separate entities but rather form part of one HF spectrum [5].
The prevalence of diabetes mellitus (DM), especially type 2 DM, 
is steadily increasing [6]. Although DM is a well-known risk factor 
for atherosclerosis and for coronary artery disease (CAD), its role in 
development of HF is less established. Nevertheless, the prevalence 
of DM in HF is approximately 20-35% [7] and is somewhat higher in 
patients with HFpEF, at 30-40% [8]. HFpEF and type 2 DM commonly 
coexist. Both conditions are associated with hypertension, obesity 
and old age [1], all of which promote the occurrence of HF. However, 
irrespective of underlying cardiovascular disease, DM has a crucial 
role in HFpEF as demonstrated in the CHARM study whereby the 
relative risk of cardiovascular death or HF hospitalization conferred by 
DM was significantly greater in patients with HFpEF compared with 
those with HFrEF [9]. The prevalence of HFpEF may be high even in 
asymptomatic and well-controlled diabetic subjects [10,11]. Despite 
the increased prevalence and poor outcome, pathophysiological 
features underlying HFpEF in DM remain uncertain, and will therefore 
be addressed hereunder.
Methods
A systematic review of the published literature was performed using 
Medline and Embase as computerized databases. The search included 
all published papers up to 21st May, 2011. The terms “heart failure 
with preserved ejection fraction”, “heart failure with normal ejection 
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fraction” and “diastolic dysfunction” in association with “diabetes 
mellitus”, were utilised in the search strategy.
1. Physiological Abnormalities associated with HFpEF in Diabetes
Four sets of guidelines have been published for the diagnosis of 
HFpEF [5,12-14]. They all require the simultaneous and obligatory 
presence of signs and/or symptoms of HF, normal LV ejection fraction, 
and evidence of diastolic LV dysfunction or of surrogate markers of 
the latter, e.g. LV hypertrophy, left atrial enlargement, atrial fibrillation, 
or elevated plasma natriuretic peptide levels. Although evidence of 
diastolic dysfunction forms an integral part in the diagnostic algorithms 
of HFpEF, this does not mean that it represents the sole contributor 
to disease pathophysiology. It is being increasingly recognized that 
other mechanisms play important roles, mainly resting and exercise-
exacerbated systolic dysfunction [14-19], impaired ventricular–vascular 
coupling [17,18,20,21], abnormal exercise-induced and flow-mediated 
vasodilation [15-17,22], chronotropic incompetence [15,17,18,23], 
and pulmonary arterial hypertension [24,25]. The risk factors for 
progression to HFpEF are variable according to the underlying 
diseases [26]. However, many of the mechanisms above-mentioned 
are thought to play a role in the pathophysiology of HFpEF in DM.
1A.  Left Ventricular Diastolic Dysfunction
LV diastolic dysfunction has been suggested as the first manifestation 
of diabetic heart disease in both type 1 and type 2 DM patients [27,28] 
(Figure 1). In the Strong Heart Study [30], which investigated the 
effect of DM on LV filling pattern in normotensive and hypertensive 
individuals, type 2 DM was associated with an impaired relaxation 
pattern independently of age, blood pressure (BP), LV mass and LV 
systolic function. The combination of DM and hypertension resulted 
in more severe abnormal LV relaxation than groups with either 
condition alone, suggesting a synergistic deleterious effect when 
both conditions were present. Moreover, abnormal relaxation in DM 
subjects was associated with higher fasting glucose and glycated 
haemoglobin (HbA1c) levels. The impact of poor glycaemic control 
on development of HF was also demonstrated in a registry of 49,000 
DM individuals whereby each 1% increase in HbA1c was associated 
with an 8% increased risk of HF [31].
The mechanical processes of diastole can be divided into active 
relaxation and passive compliance, both of which can be affected. In 
the absence of endocardial/pericardial disease, diastolic dysfunction 
results from increased myocardial stiffness that is determined by 
the extracellular matrix and the cardiomyocytes. In addition, both 
compartments influence each other via matricellular proteins. The 
actual contribution of LV relaxation and compliance to the development 
of HFpEF in DM is still unclear. In a study by Takeda et al [26] on 544 
Japanese DM patients with ejection fraction (EF) ≥50%, female sex, 
high body mass index, low haemoglobin, and low diastolic wall strain 
(DWS) were independently associated with the prevalence of HFpEF. 
A low DWS indicates impairment of LV compliance [32]. On the other 
hand, the decrease in E velocity, an index of LV relaxation, was not 
independently associated with HFpEF. This was a cross-sectional one 
and thus subject to various limitations, including survival bias and 
inability to assess cause and effect. Nonetheless, the impaired LV 
compliance noted is known to be associated with increased collagen 
accumulation and enhanced collagen cross-linking [33]. In DM, 
there is increased myocardial deposition of collagen and advanced 
glycation end- products (AGEs) which promote cross-linking [34]. 
Willemsen et al [35] have shown that DM HF patients had higher 
tissue AGEs and poorer exercise capacity than those without DM. 
Also, tissue AGEs correlate with mean E’ in DM, suggesting a close 
relationship between tissue AGEs, diastolic function, and exercise 
capacity independent of EF.
The findings of Takeda et al [26] contrast with those of van 
Heerebeek et al [36]. The latter used LV endomyocardial biopsy 
samples from 64 patients (26 diabetic), to compare myocardial fibrosis, 
AGE deposition, and cardiomyocyte resting tension (Fpassive) of 
isolated cardiomyocytes between DM and non-DM HFpEF patients 
and between DM and non-DM HFrEF patients. All patients had been 
hospitalized for worsening HF and none had CAD. It was shown 
that DM HFpEF patients had increased LV myocardial stiffness 
(assessed by radial LV stiffness modulus) in comparison to non-
DM patients with HFpEF. Furthermore, the increased diastolic LV 
stiffness was related more to cardiomyocyte Fpassive and less 
to AGE deposition. On the other hand, in DM HFrEF patients, the 
higher diastolic LV stiffness was related to both AGE deposition and 
interstitial fibrosis. The authors suggest that the high cardiomyocyte 
Fpassive is probably secondary to a phosphorylation deficit of 
myofilamentary or cytoskeletal proteins [37,38]. High Fpassive was 
accompanied by Z-line widening, suggesting that Z-line widening 
results from altered elastic properties of cytoskeletal proteins that 
pull at and open up adjacent Z lines. Also, Fpassive rose progressively 
from HFrEF to HFpEF in non-DM to HFpEF in DM, and this rise was 
paralleled by an increase in cardiomyocyte diameter and a shift 
from eccentric to concentric LV remodeling. All of the HFpEF DM 
patients had type 2 DM and fasting hyperinsulinaemia. They thus 
suggest that the excess cardiomyocyte hypertrophy in DM HFpEF is 
probably secondary to insulin resistance since hyperinsulinaemia is 
known to stimulate prohypertrophic signaling in insulin-responsive 
tissues e.g. the myocardium [39].
The population studied by van Heerebeek et al showed different 
clinical characteristics to those observed in epidemiological studies. 
Thus, as suggested by Connelly et al [40], one should not conclude 
that fibrosis does not contribute to HFpEF in DM. Animal studies 
suggest that fibrosis contributes to this syndrome [41], while human 
studies have shown that collagen volume fraction is increased 
approximately 2-fold in both DM and non-DM subjects with HFpEF 
[42]. It seems that both fibrosis and cardiomyocyte Fpassive are linked 
attributes to HFpEF in DM though the relative contribution of each 
remains under debate. Undoubtedly, research into new treatment 
strategies should include both antifibrotic and antihypertrophic 
strategies [40].  
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1B. Ventricular-arterial Coupling & Vascular Dysfunction
EF is preserved in HFpEF, but EF is more accurately regarded 
as a measure of ventricular–arterial coupling than contractility 
alone [41]. Ventricular–arterial coupling can be expressed as the 
ratio of arterial elastance to end-systolic elastance [43]. Elastance is 
a measure of stiffness. Arterial elastance is determined by peripheral 
vascular resistance, total arterial compliance, impedance, and 
systolic and diastolic time intervals [44] and therefore represents 
the arterial afterload on the LV. In healthy subjects, ventricular-
arterial coupling maintains this ratio within narrow limits, so as to 
optimise the energy efficiency of the myocardium.
However, ageing, hypertension, and DM lead to ventricular and 
vascular stiffening, with consequent HFpEF [8,45], the latter leading 
to greater BP lability with amplified BP changes for any alteration 
in preload/afterload [46]. Thus, although ventricular-arterial 
coupling appears beneficial in maintaining optimal cardiovascular 
performance [47,48], ultimately it results in adverse cardiovascular 
effects, including increased sensitivity to volume shifts and 
decreased exercise capacity [49]. Ventricular-arterial coupling 
may be particularly relevant in DM. The brachial-ankle pulse wave 
velocity (baPWV), an indirect surrogate of vascular compliance, is 
increased in DM subjects as compared with normal subjects [50]. 
Figure 1. Left Ventricular Diastolic Dysfunction
Doppler evidence of left ventricular diastolic dysfunction: (A) Mitral inflow pattern show-
ing reversed E/A ratio; (B) Tissue Doppler evidence indicating diastolic dysfunction.
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Similarly, in the Digitalis Investigation Group (DIG) ancillary study, 
a higher pulse pressure was noted in HFpEF patients with DM 
compared to non-DM patients [51]. Increased arterial stiffness in 
DM is probably secondary to AGEs; this could have contributed 
to the increased risk of adverse cardiovascular outcomes in DM 
HFpEF patients [51]. 
Nonetheless, the role of ventricular-arterial coupling in DM 
patients with HFpEF is still controversial. In the study by Takeda 
et al [26], there was no difference in baPWV between DM subjects 
without HF and DM subjects with HF while Poulsen et al [52] have 
shown that valvulo-arterial impedance (p=0.027) and summed 
stress score, an indicator of myocardial ischaemia (p<0.001), are 
independent predictors of grade 2 diastolic dysfunction in type 2 
DM, though only summed stress score (p<0.001) was a predictor 
of left atrial dilation. Taken together, these results suggest that 
ventricular-arterial coupling might play a role in the development 
of HFpEF in DM.
Systemic vasorelaxation with exercise is attenuated in 
HFpEF [15-17], promoting impaired delivery of blood flow to 
skeletal muscle. Vascular dysfunction in HFpEF may be partly 
secondary to endothelial dysfunction, as suggested by Borlaug et 
al [17] whereby impaired flow-mediated vasodilation was noted in 
HFpEF compared with healthy age-matched controls. Endothelial 
dysfunction is a common finding in DM, as discussed below.
1C. Chronotropic Incompetence & Cardiovascular Reserve 
Dysfunction
Various studies have highlighted the importance of abnormalities 
in cardiovascular reserve function with exercise stress in HFpEF 
[15-20,23], explaining why most patients with HFpEF complain of 
symptoms only on exertion. Normal exercise reserve function is 
determined by diastolic reserve, systolic reserve and chronotropic 
reserve. Abnormalities in each of these components have been 
identified in HFpEF, including subjects with DM. 
Diastolic reserve is reduced in HFpEF such that patients display 
blunted increases in preload volume with exertion, despite marked 
elevations in filling pressure. In a comprehensive study using 
upright bicycle exercise testing with simultaneous right heart 
catheterization and serial radionuclide ventriculography [53], 
cardiac index, stroke volume index, and LV end-diastolic volume 
(LVEDV) at rest did not differ between HFpEF patients, some of 
whom were diabetic, and control subjects but were lower in 
patients with HFpEF at peak exercise. This resulted in markedly 
lower peak oxygen consumption. The authors suggest that this is 
secondary to impaired LV filling and failure to use the Frank-Starling 
mechanism properly [48]. An impaired chronotropic response was 
also reported. This is probably related to downstream deficits in 
β-adrenergic stimulation since there is a similar increase in plasma 
catecholamines with exercise in HFpEF and healthy controls [15]. 
This is possibly secondary to autonomic dysfunction, a common 
co-morbidity in DM, since baroreflex sensitivity is reduced and 
heart rate recovery impaired in HFpEF [15,54].
In a study by Borlaug et al [15], HFpEF patients, most of whom were 
diabetic, showed a lower increase in heart rate, lower decrease in 
systemic vascular resistance index, and lower increase in cardiac 
index during exercise when compared with controls while LVEDV 
increased similarly in both groups. These findings suggest that 
in HFpEF both the chronotropic and vasodilatory reserves are 
diminished [15]. The latter would result in reduced diastolic 
reserve. In another study by Westermann et al [55], a decrease 
in LVEDV and stroke volume were noted in HFpEF patients (17% 
diabetic) during pacing at 120 beats/min; this was interpreted as 
manifestation of increased LV stiffness. However, during handgrip, 
a more physiologic form of exercise, there was no change in LVEDV. 
In view of these contradictory results, further studies are needed 
to understand the haemodynamic response to exercise in HFpEF.
With respect to systolic reserve, blunted increases occur in 
EF, contractility, and longitudinal systolic shortening velocities 
during exercise [15-19]. It has been suggested that myocardial 
ischaemia (epicardial/microvascular coronary disease or vascular 
rarefaction), impaired β-adrenergic signalling [56], myocardial ener- 
getics [18,57], and abnormal calcium handling [58] play a role 
in systolic and diastolic reserve dysfunction in HFpEF. These 
pathological changes have been noted in DM (discussed below).
2. Pathophysiological Mechanisms underlying HFpEF in Diabetes
Various morphologic changes occur in the diabetic heart leading 
to the abnormal physiological findings described above. These 
include increased extracellular collagen deposition, interstitial 
fibrosis, myocyte hypertrophy and intramyocardial microangiopathy. 
These changes are probably secondary to altered myocardial 
glucose and free fatty acid metabolism (FFA) in DM as outlined 
below and in Figure 2.
2A. Hyperglycaemia
The hallmark of type 2 DM is insulin resistance with impaired 
myocardial glucose use and increased turnover of FFAs, leading 
to myocardial lipotoxicity, uncoupling of mitochondrial 
oxidative phosphorylation and disturbed contraction/relaxation 
coupling [59]. In type 1 DM, even though no hyperinsulinaemia is 
usually present, hyperglycaemia secondary to β-cell failure leads 
to numerous adverse cellular effects including down-regulation 
of sarcoplasmic reticulum calcium ATPase (SERCA) expression 
and activity, decreased Na+/K+-ATPase function and decreased 
myocardial flow reserve, leading to both LV systolic and diastolic 
dysfunction [60]. Furthermore, diminished C-peptide levels in type 
1 DM may adversely affect cardiac endothelial function [61,62], 
probably through diminished nitric oxide release [63].
Glycaemic control has been reported to improve diastolic 
dysfunction [64] and to reduce LV mass [65] over a 6-12 month 
period. It is important to note that good glycaemic control may 
also be a marker of improved metabolic control including free 
fatty acid concentration. 
Magri et al. Journal of Diabetes Research and Clinical Metabolism 2012, 
http://www.hoajonline.com/journals/pdf/2050-0866-1-2.pdf 5
2B. Lipotoxicity 
Diabetic subjects exhibit increased myocardial fat [66] and this 
is associated with diastolic dysfunction [67]. In both type 1 and 
type 2 diabetes, the myocardium is increasingly dependent on 
fatty acid rather than glucose metabolism for its energy require- 
ments [68]. Since fatty acid metabolism requires more oxygen 
for energy production, it may lead to relative hypoxia. This may 
predispose to diastolic dysfunction [68] as ventricular relaxation 
is an energy-dependent process. Furthermore, intermediates of 
fat metabolism, such as ceramide might be toxic, inducing cell 
apoptosis [69].
2C. Hyperinsulinaemia
HFpEF is not only associated with diabetes but also with the 
metabolic syndrome [70] and with impaired glucose tolerance 
[71], suggesting that insulin resistance and/or hyperinsulinaemia 
might be implicated. Nichols et al [72] reported that insulin use was 
associated with both prevalent and incident HF. In the Uppsala 
Longitudinal Study of Adult Men, baseline fasting proinsulin and 
insulin resistance predicted future HF [73].
Cardiomyocyte-selective insulin receptor knockout mice show 
reduced cardiac and cardiomyocyte size [74]. In humans, insulin 
levels have been associated with LV relative wall thickness [75]. 
Figure 2. Pathophysiological Mechanisms
Pathophysiological mechanisms underlying HFpEF in diabetes mellitus 
(RAS: renin-angiotensin system)
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Insulin is a growth factor to many cells types, including the 
cardiomyocyte. The signaling pathways mediating the metabolic 
and growth factor properties of insulin are different. Crucially, 
insulin resistance seems to affect only the metabolic, but not the 
growth factor, effects of insulin. Therefore hyperinsulinaemia in 
subjects with type 2 DM or the metabolic syndrome exposes them 
to exaggerated growth factor-like effects. 
2D. Advanced glycation endproducts (AGEs)
Chronic hyperglycemia leads to non-enzymatic glycation of 
matrix proteins in the vascular wall and myocardium, producing 
AGEs. AGEs stimulate collagen production and cross-linkage, 
leading to increasing LV diastolic stiffness and diminished 
compliance of the blood vessels [76]. AGEs increase oxidative 
stress and pro-inflammatory cytokine release while AGE receptor 
activation induces pro-fibrotic signaling and impairs calcium 
homeostasis [77,78]. Increased serum AGEs are associated with LV 
diastolic stiffness, endothelial dysfunction, impaired vascular 
compliance and reduced NO bioavailability, in both type 1 and 2 
DM patients [77,78].
2E. Impaired calcium homeostasis
Calcium handling by the cardiomyocyte is important in both systole 
and diastole. Membrane depolarization results in the release of 
calcium from the sarcoplasmic reticulum (SR) into the cytosol 
(through ryanodine receptors), where it binds troponin C to start 
the contractile process. During diastole, calcium is taken up by 
the SR through activation of the SR calcium+ pump (SERCA2a), 
the sarcolemmal Na+-Ca2+ exchanger, and the sarcolemmal 
Ca2+ ATPase.
In both type 1 and 2 DM, disturbed cardiomyocyte calcium 
handling results from reduced activity of calcium handling proteins, 
such as SERCA2a, ryanodine receptor, Na2+/-Ca2+ exchanger 
and sarcolemmal Ca2+ ATPase. This leads to impaired excitation-
contraction coupling and LV systolic and diastolic dysfunction [59,79].
2F. Myocardial Oxidative Stress
Hyperglycaemia induces oxidative stress via several mechanisms, 
mainly glucose auto-oxidation, formation of AGEs, activation of 
the polyol pathway and increased levels of FFAs and leptin [80]. 
Cardiovascular sources of reactive oxygen species (ROS) production 
include xanthine oxidoreductase, nicotinamide adenine dinucleotide 
3-phosphate (NAD(P)H) oxidase, mitochondrial oxidases and 
uncoupled nitric oxide (NO) synthases [80,81]. Increased generation 
of ROS leads to cardiac injury and endothelial dysfunction, by direct 
oxidative cellular damage and by diminished NO bioavailability [81].
2G. Myocardial Fibrosis
Increased collagen deposition occurs in the diabetic myocardium, 
as evidenced by abnormal increased backscatter on echocardio- 
graphy [82].  Hyperglycaemia, oxidative stress and elevated 
aldosterone and angiotensin II levels lead to increased expression 
of collagen type I and downregulation of collagen-degrading 
matrix metalloproteinases [82].
2H. Left Ventricular Hypertrophy
LV hypertrophy is commoner in diabetic subjects, independently 
of BP and other factors [83,84]. This can be mediated through 
hyperinsulinaemia and/or insulin resistance (see above). 
Various adipokines may also be implicated. These include resi- 
stin [85] (a cytokine released by adipose tissue macrophages) and 
leptin [86] (a marker of fat mass), both of which are increased in 
type 2 diabetes and the metabolic syndrome.
2I. Endothelial dysfunction
Altered insulin signaling, glyco- and lipotoxicity, and AGEs 
accumulation, all factors that occur in DM, lead to endothelial 
dysfunction [87]. This results in dysregulation of vascular permeability, 
inflammatory responses, vascular remodelling and atherosclerosis, 
with consequent increased arterial stiffness, BP and pulse 
pressure [88,89]. The increase in afterload results in increased resting 
myocardial oxygen requirements and in myocardial hypertrophy 
which ultimately leads to LV diastolic dysfunction [90].
2J. Microangiopathy
Diabetic patients exhibit microangiopathy that is characterized 
by abnormal capillary permeability, microaneurysm formation, 
subendothelial matrix deposition, and fibrosis surrounding 
arterioles [91]. This impairs oxygen delivery to myocardial cells. 
Interestingly, coronary blood flow reserve is reduced in DM even in 
the absence of obstructive CAD [92,93]. Thus, myocardial ischaemia 
may play a role in diastolic dysfunction in DM in the absence of 
significant CAD since myocardial relaxation is an energy-dependent 
process. This can be further exacerbated by dependence on fatty 
acids as an energy substrate, mitochondrial uncoupling (see above) 
and LV hypertrophy that increases the diffusion distance between 
blood in the microcirculation and parts of the myocardium. 
2K. Neurohormonal Regulation
Hyperglycaemia and hyperinsulinaemia activate the cardiac 
renin-angiotensin system (RAS) by increasing the expression 
of angiotensinogen, angiotensin II, and angiotensin II type 1 
receptor. This contributes to diastolic dysfunction via hypertension 
and impaired myocardial relaxation [94-96]. Myocardial RAS 
activation has been demonstrated in streptozocin-induced diabetic 
rats [97].
2L. Autonomic Neuropathy
Diabetic autonomic neuropathy affects both the sympathetic and 
parasympathetic nervous system; this has been associated with 
impaired systolic and diastolic function [98]. In transgenic mice, 
an increased expression of the β1-receptor results in enhanced 
apoptosis, fibrosis, hypertrophy, and impaired myocardial 
function [99].
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2M. The Foetal Gene Programme
This entails the expression of genes normally expressed in 
foetal/early neonatal life. Re-expression of the foetal gene 
programme might be an adaptive response in the failing heart. It 
leads to upregulation of the β-myosin heavy chain (β-MyHC) gene 
and down-regulation of the fast contracting isoform, α-MyHC [100]. 
These changes may be adaptive: β-MHC would allow cardiac muscle 
to work more efficiently when chronically overloaded because it 
contracts and relaxes more slowly than α-MHC [101]. However, 
it may predispose to diastolic dysfunction as demonstrated in 
alloxan-induced diabetic rats [102].
2N. Stem Cell involvement
LV dysfunction in DM might be a stem cell disease. Rota et al [103] 
have shown that enhanced oxidative stress in DM can affect cardiac 
progenitor cell function leading to defective myocyte formation, 
premature myocardial aging and HF. It has been suggested that 
the p66shc gene is responsible for promoting the senescent 
phenotype [103].
2O. Other Myocardial Changes in Diabetes
Other changes at the molecular level include altered protein kinase 
C metabolism resulting in endothelial dysfunction, increased 
leukocyte adhesion, increased albumin permeability, and impaired 
fibrinolysis [104,105]; impaired myocardial NO bioavailability 
resulting in increased LV diastolic stiffness [106]; and impaired 
myocardial cGMP synthesis leading to impaired protein kinase 
G (PKG) activity. PKG has anti-hypertrophic, anti-remodeling and 
anti-inflammatory actions [107]. Downregulation of NO-mediated 
cGMP-PKG signalling, probably induced by vascular inflammation 
and oxidative stress, could account for the high Fpassive of 
hypertrophied cardiomyocyte observed in DM HFpEF patients [108].
Conclusion
Although various studies have been performed to unravel the 
pathophysiology of HFpEF in diabetic patients, a lot is still 
unknown. The key issue is that diabetic individuals are at increased 
risk of HF, particularly HFpEF with associated poor prognosis. 
Therapeutic options for HFpEF are still controversial. Thus, 
currently, cardiometabolic prevention, focusing on dyslipidaemia, 
hypertension and hyperglycaemia, should form the cornerstone in 
the management of DM patients. Undoubtedly, further studies are 
needed to establish the pathophysiological mechanisms underlying 
HFpEF in DM with the hope that novel pharmacotherapies targeting 
this disease will be developed.
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